Potential new therapies for the treatment of HIV-1 infection

Annual Review of Medicine

Volumn 53, Issue , 2002, Pages 541-555

  Condra, Jon H ^a   Miller, Michael D ^a   Hazuda, Daria J ^a   Emini, Emilio A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Assembly inhibitors; Entry inhibitors; Integrase; Protease; Reverse transcriptase

Indexed keywords

1,3 DIKETO ACID DERIVATIVE; 4 (2 CYCLOPROPYLVINYL) 5,6 DIFLUORO 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; 4 CYCLOPROPYLETHYNYL 5,6 DIFLUORO 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; 6 CHLORO 4 (2 CYCLOPROPYLVINYL) 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; 6 CHLORO 4 CYCLOPROPYLETHYNYL 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; ATAZANAVIR; CD4 IMMUNOGLOBULIN G2; DAPIVIRINE; DIAMINOPURINE DIOXOLANE; DIDANOSINE; DIOXOLANE GUANOSINE; DPC 681; DPC 684; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; INTEGRASE INHIBITOR; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; TIPRANAVIR; TMC 126; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CLINICAL TRIAL; DRUG MECHANISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; METABOLIC DISORDER; NONHUMAN; PATIENT COMPLIANCE; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VIRUS ASSEMBLY; VIRUS RESISTANCE;

ANIMALS; ANTI-HIV AGENTS; DRUGS, INVESTIGATIONAL; HIV INFECTIONS; HIV-1; HUMANS;

EID: 0036180884     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.53.082901.104110     Document Type: Review

References (76)

1. Rational approach to drug design through structural biology
2. Crystal structure of HIV-1 reverse transcriptase with template-primer terminated with the acyclic nucleotide reverse transcriptase inhibitor tenofovir
3. Anti-HIV activity profile of tenofovir (PMPA) against a panel of nucleoside-resistant clinical samples
4. Mutations in retroviral genes associated with drug resistance: 2000-2001 update
5. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
6. DAPD: A novel nucleoside inhibitor of HIV-1 replication, is active against drug-resistant isolates of HIV-1 from patients failing standard nucleoside therapy
7. In vitro selection experiments demonstrate reduced development of resistance with TMC 120 and TMC 125 compared with first generation non-nucleoside reverse transcriptase inhibitors
8. Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors
9. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human-immunodeficiency-virus protease inhibitor
10. Tipranavir (PNU-140690): A potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class
11. In vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors
12. Inhibitors of human immunodeficiency virus integrase
13. Retroviral integrase inhibitors year 2000: Update and perspectives
14. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells
15. Retroviruses
16. HIV integrase structure and function
17. Discovery and analysis of inhibitors of the human immunodeficiency integrase
18. Retroviral integrase functions as a multimer and can turn over catalytically
19. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase
20. A quantitative assay for HIV DNA integration in vivo
21. 4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells
22. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens
23. HIV entry and its inhibition
24. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease
25. Structure of influenza haemagglutinin at the pH of membrane fusion
26. A spring-loaded mechanism for the conformational change of influenza hemagglutinin
27. Influenza hemagglutinin is spring-loaded by a metastable native conformation
28. Core structure of gp41 from the HIV envelope glycoprotein
29. Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41
30. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates
31. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG
32. Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules
33. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults
34. Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: Phase 1/2 study
35. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor
36. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100
37. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4
38. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 coreceptor
39. Antiviral efficacy in vivo of the antihuman immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry
40. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers
41. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor
42. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection
43. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: A strong anti-HIV peptide T140
44. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment
45. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice
46. A cell-autonomous requirement for CXCR4 in long-term lymphoid and myeloid reconstitution
47. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
48. Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: Synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety
49. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5
50. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140
51. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. 1. Discovery and initial structure-activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl)butanes
52. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. 2. Structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4- (piperidin-1-yl)butanes
53. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. 1. Discovery of the pyrrolidine scaffold and determination of its stereochemical requirements
54. A synthetic peptide inhibitor of human immunodeficiency virus replication: Correlation between solution structure and viral inhibition
55. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection
56. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
57. A controlled phase II trial assessing three doses of T-20 in combination with abacavir, amprenavir, low dose ritonavir and efavirenz in non-nucleoside naïve protease inhibitor experienced HIV-1 infected adults
58. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides
59. A 14-day assessment of the safety, pharmacokinetics, and antiviral activity of T-1249, a peptide inhibitor of membrane fusion
60. HIV-1 gag proteins: Diverse functions in the virus life cycle
61. The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release
62. Tripeptides that inhibit HIV- 1: Discovery and mode of action
63. The nontoxic tripeptide glycyl-prolyl-glycine amide inhibits the replication of human immunodeficiency virus type 1
64. Deletion of the GPG motif in the HIV type 1 V3 loop does not abrogate infection in all cells
65. The tripeptide glycyl-prolyl-glycine amide does not affect the early steps of the human immunodeficiency virus type 1 replication